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Abstract
Introduction: From the travel ban on people living with HIV (PLHIV) to resistance to needle exchange programmes, there are
many examples where policy responses to HIV/AIDS in the United States seem divorced from behavioural, public health and
sociological evidence. At its root, however, the unknowns about HIV/AIDS lie at biomedical science, and scientific researchers
have made tremendous progress over the past 30 years of the epidemic by using antiretroviral therapy to increase the life
expectancy of PLHIV almost to the same level as non-infected individuals; but a relationship between biomedical science
discoveries and congressional responses to HIV/AIDS has not been studied. Using quantitative approaches, we directly examine
the hypothesis that progress in HIV/AIDS biomedical science discoveries would have a correlative relationship with congressional
response to HIV/AIDS from 1981 to 2010.
Methods: This study used original data on every bill introduced, hearing held and law passed by the US Congress relating to HIV/
AIDS over 30 years (19812010). We combined congressional data with the most cited and impactful biomedical research
scientific publications over the same time period as a metric of biomedical science breakthroughs. Correlations between
congressional policy and biomedical research were then analyzed at the aggregate and individual levels.
Results: Biomedical research advancements helped shape both the level and content of bill sponsorship on HIV/AIDS, but they
had no effect on other stages of the legislative process. Examination of the content of bills and biomedical research indicated
that science helped transform HIV/AIDS bill sponsorship from a niche concern of liberal Democrats to a bipartisan coalition when
Republicans became the majority party. The trade-off for that expansion has been an emphasis on the global epidemic to the
detriment of domestic policies and programmes.
Conclusions: Breakthroughs in biomedical science did associate with the number and types of HIV/AIDS bills introduced in
Congress, but that relationship did not extend to the passage of laws or to hearings. When science matters, it cannot be
separated from political considerations. An important implication of our work has been the depoliticizing role that science can
play. Scientific breakthroughs helped to transform HIV/AIDS policy from a niche of liberal Democrats into bipartisan support for
the global fight against the disease.
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Introduction
On 30 October 2009, President Barack Obama announced
that his administration was ending the travel ban against
people living with HIV (PLHIV). Obama described the travel
ban as ‘‘a decision rooted in fear rather than fact’’ [1]. In
the early days of HIV, when it was called GRID (gay-related
immunodeficiency), there was perhaps some basis for the
fears that Obama references: pre- and postnatal infant
infections [2,3], blood transfusions [4], infected healthcare
workers [5] and female heterosexual acquisition [6]. When
Congress statutorily enforced the travel ban in 1993 [7], there
had been significant advances in understanding transmission
[3,811], virus detection even in asymptomatic individuals
[12] and extending lives with antiretrovirals [13,14]. Despite
these important advances, the spectres of Ryan White,
Arthur Ashe, Magic Johnson and dentists infecting their
patients [10,11] were enough to sustain public fears.
The travel ban is an example of the US Congress responding
to public fear and giving it priority over scientific knowledge.
Thisincidentisnotisolatedfromothercongressionaldecisions
regardingHIV/AIDS.Behavioural,publichealthandsociological
studies have been disregarded: examples include laws dis-
allowing federal funds for needle exchange programs despite
their well-documented efficacy for reducing HIV transmission
[9,15,16], laws disallowing condom distribution in prisons [17]
and the lack of antiretroviral drug availability for the working
poor and middle class domestically. Congress has seemed
out of step with recommendations from social scientists and
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1public health experts. HIV/AIDS is a biomedical problem with
scientific discovery developing new ways to combat it. In this
article, we ask: what role has biomedical scientific discovery
played in the congressional response to HIV/AIDS?
At its core, this is a study of how and whether science
interacts with politics. The science for policy literature
suggests that climate change, like HIV/AIDS, is a case where
science has been politicized [18]. Jasanoff states that the
credibility, trust and validity of science are necessary for
scientific progress and public support [19]. Building trust
between scientists and the public falls on the scientist,
scientific knowledge and the committee advisors who trans-
late these findings for policy purposes [19,20]. In a stylized
world, scientific findings are divorced from ideology and
partisanship. Debates on climate change took place in a real
world where the public lost trust in scientists and detached
from their policy positions [19]. As a result, Montpetit argues
that climate knowledge is viewed along existing political
divisions instead of as objective truth [21].
There are important differences between climate change
and HIV/AIDS policy. Firstly, detached HIV/AIDS activists are
not possible because the need for treatment ties them to
the biomedical community [22]. Secondly, climate change is a
long-term, collective disaster, whereas HIV/AIDS (if left
untreated) is short term and personal. Biomedical advance-
ments that have extended life to within 10 years of the non-
infected life expectancy should reinforce trust in scientists.
Along with properly controlled experiments, the rigors of
peer review and the clinical evidence of treatments working,
presumably without political agenda [23], should create trust
between biomedical scientists and the government.
Despite these apparent differences between climate
change and HIV/AIDS, their policy fates may be inevitably
similar. Guston and colleagues posit that scientific knowledge
is not separable from ideology, but has inherent partisanship
[24]. A comprehensive study by Hoppe finds a strong
consensus that scientific experts and advisors are not
partisan and that scientists help to depoliticize hot topics
[25]. However, scientific advisors overwhelmingly agreed that
scientific expertise plays only a moderate role in policy, and
that politics and values are the major influence. Science was
used for ‘‘uncertainty reduction.’’ We contribute to this
literature by quantitatively testing the hypothesis that
biomedical science discoveries in the 30-year fight against
HIV/AIDS have a correlative relationship with the congres-
sional response to HIV/AIDS.
Methods
Study design
This is a statistical analysis of how congressional policy
making  bills introduced, hearings held and laws passed 
correlates with the annual number of scientific, biomedical
breakthroughs published from 1981 to 2010.
Data collection
HIV/AIDS biomedical scientific literature collection
HIV/AIDS scientific breakthroughs were defined using the
most-cited biomedical articles and journals with the highest
impact factors (Table 1). Using the Web of Science database
(Thomson Reuters) and appropriate search terms, the 500
most-cited articles on HIV/AIDS were identified, and the
annual number of articles published from 1981 to 2010 was
counted. Articles were ranked by citations per year to avoid
bias towards older articles. This measure of scientific knowl-
edge is in line with standard conventions [18]. The cut-off at
500 was arbitrary but sufficient to focus on the most
important advances and publications. To confirm reliability,
neither the sign nor the significance of results changed when
articles were cut off at 1000.
As a supplement, a list of important articles was compiled
based on our own literature review. This supplemental list
allowed the inclusion of influential articles that were pub-
lished before the HIV/AIDS nomenclature was used or
that were not among the top cited but are referenced at
international conferences.This included the earlieststudies by
Montagnier and Gallo from 1981 to 1987, which were nicely
summarized[8]duringthesettlementbetweentheseresearch
groups and their governments over initial HIV patents [8,26].
Articles were coded by general subject: transmission, cure,
medicine, identification, pathogenesis, women and children,
healthcare, homosexual, comorbidities and global epidemic.
Congressional policy making
The Congressional Hearing Digital Archive maintained by
LexisNexis was searched using ‘‘acquired immune deficiency
Table 1. Biomedical journals with the highest impact factors
and top-cited publications for HIV/AIDS research
Impact
rank Journal title
Impact
factor
3 New England Journal of Medicine 53.5
8 Nature Genetics 36.4
9 Nature 36.1
11 Lancet 33.6
14 Cell 32.4
15 Science 31.4
18 Journal of the American Medical Association 30.0
31 Nature Immunology 25.7
32 Nature Medicine 25.4
45 Nature Cell Biology 19.4
58 Annals of Internal Medicine 16.7
63 PLOS Medicine 15.6
69 Journal of Experimental Medicine 14.8
76 Journal of Clinical Investigation 14.2
91 Genes and Development 12.9
96 PLOS Biology 12.5
124 Blood 10.6
151 Proceedings of the National Academies of Science 9.8
214 Cancer Research 8.2
312 AIDS 6.3
384 Journal of Immunology 5.7
427 Journal of Biological Chemistry 5.3
456 Journal of Virology 5.2
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2syndrome’’ to identify hearings related to HIV/AIDS from
1981 to 2010. Our dependent variable for hearings was the
yearly count of HIV/AIDS hearings in Congress. Data on bill
sponsorship and laws passed were also collected. Using the
THOMAS database maintained by the US Library of Congress,
searches for ‘‘AIDS (Disease),’’ ‘‘human immunodeficiency
virus’’ and ‘‘HIV/AIDS’’ were completed. Bills identified from
these searches were then cross-referenced with the Con-
gressional Bills Project database. The bills variable was the
yearly count of HIV/AIDS bills introduced in Congress, and the
laws variable was the yearly count of HIV/AIDS bills enacted
into law. Bills on HIV/AIDS were also coded by subject for
consistent comparison to scientific breakthroughs.
Control variables
Media coverage [27], partisanship and major HIV/AIDS events
in the United States were controlled in the following ways.
‘‘Acquired immune deficiency syndrome’’ was used to search
the New York Times in LexisNexis, and the news variable was
the yearly count of those identified articles. We operationa-
lized partisanship to take the value of 1 when Democrats
held a majority in both houses of Congress, 0 when control
was split and 1 when Republicans were the majority [18].
Major events was a dummy variable that took the value of
1 for years involving major non-scientific HIV/AIDS events and
zero for all others. Major-event years were 1983, when the
US Centers for Disease Control and Prevention officially
acknowledged AIDS; 19851987, when Ryan White was in
the press, President Ronald Reagan spoke about AIDS for the
first time and azidothymidine was introduced; 19911992,
when Magic Johnson announced his status of living with HIV;
and 1994, when AIDS became the leading killer of men aged
2544 in the United States.
Analysis
Statistical software R was used for statistical analysis.
Augmented DickeyFuller tests showed that none of the
five time trends  bills, hearings, laws, scientific break-
throughs or newspaper articles  followed stationary pro-
cesses. Vector auto-regression (VAR) allowed estimation of
the relationship between scientific breakthroughs and con-
gressional response to HIV/AIDS while controlling for reci-
procal feedback between media coverage and congressional
policy making. The ‘‘vars’’ package was used to run separate
models for bills, hearings and laws. The congressional
measures and media attention were treated as endogenous
variables in a VAR(1) process, and breakthroughs, partisan-
ship and major events were treated as exogenous variables.
The breakthrough variable was lagged by one year to allow
time for scientific breakthroughs to work through the
political system. For example, the following equation was
used for bill sponsorship:
billst ¼ b1billst 1 þ b2newst 1 þ b3major paperst 1
þ b4democrat controlt þ b5major eventst þ e1t
newst ¼ b6billst 1 þ b7newst 1 þ b8major paperst 1
þ b9democrat controlt þ b10major eventst þ e2t
Analyzing individual-level bill sponsorship
An analysis of bill sponsorship at the individual level
supplemented the aggregate. The dependent variable was
whether or not a given member of Congress introduced any
HIV/AIDS bills in a given year. Standard political science
variables of partisanship, ideology, race, gender and institu-
tional position were included with aggregate measures of
scientific breakthroughs, media attention and major events.
Partisanship was binary: a value of 1 for Democrats and 0 for
Republicans. Ideology was measured as the common space
score from NOMINATE [28]. These scores range from 1a s
most liberal to 1 as most conservative. Institutional position
was a binary that took a value of 1 if the member was in the
majoritypartyand0otherwise.Raceandgenderwerebinaries
that took values of 1 if member was Black or a woman. Lastly,
the total number of bills that a member introduced in a year
was included to control for differences in overall legislative
activity. The individual-level analysis was conducted using a
multilevel logistic regression where effects of ideology, race
and partisanship were allowed to vary by year.
Results
Annual attention to HIV/AIDS by congressional actions,
scientific publications and popular press articles from
1981 to 2010
A data compilation of bills introduced, hearings held, laws
passed, major scientific papers published and New York Times
articles is shown as the number of each by year, from 1981 to
2010 (Figure 1). The number of bills introduced by Congress
does not correlate with the number of major scientific papers
published each year, but the number of hearings held does
look similar to the number of New York Times articles
published each year.
Top-cited HIV/AIDS biomedical papers
Looking at the most-cited article from each year between
1986 and 2011, the topics are about identification and
testing, viral pathogenesis, treatments and large-scale clinical
trials showing efficacy of treatments (Table 2).
Scientific breakthroughs correlate with bill sponsorship but
not with congressional hearings or laws being passed
Table 3 shows the estimated effects that major HIV/AIDS
scientific papers had on sponsoring bills, holding hearings
and passing laws.There was a statistically significant relation-
ship only between scientific breakthroughs and bill sponsor-
ship. Years with larger numbers of major papers on HIV/AIDS
did not correlate with more hearings or laws passed the
following year, which fits findings from the literature for
congressional attention [29,30]. Additionally, the number of
bills sponsored and laws passed concerning HIV/AIDS in-
creased in response to surges in media attention; the number
of hearings held only responded to major events. Trends for
hearings and media, illustrated by Figure 1B and 1E, fall in
line with major events that occurred between 1985 and 1987
before trailing off after the early 1990s. It seems that
congressional hearings and the media move in sync to pay
attention to major events relating to HIV/AIDS.
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3Merging political science and biomedical science to
explain HIV/AIDS bill sponsorship
In the aggregate, biomedical science has played a role in
getting HIV/AIDS bills sponsored but not passed into law.This
also held at the individual level (Table 4).
Figure 2A illustrates how the probability of bill sponsorship
increased when the number of major scientific papers pub-
lishedeachyearincreased.Giventherelativelylowprobability
thatamemberofCongresswouldintroduceHIV/AIDSbills,the
threefold change from 3 to 9% (over a range from 0 to 35
papers) could be considered substantial.
Ideology also had dramatic effects on introducing HIV/AIDS
legislation (Figure 2B). Conservative members of Congress
were far less likely to introduce bills on HIV/AIDS issues.
Women were 1% more likely to sponsor legislation. Being in
the majority party has consistently been related to increases
in bill sponsorship [31,32] and conveys a two-percentage-
point increase for introducing HIV/AIDS bills. Republicans
being two percentage points more likely to introduce HIV/
AIDS bills initially seems counterintuitive. The correct inter-
pretation is that liberal and moderate Republicans are more
active than conservative Democrats. For example, there are
eleven members of Congress (MCs) who fall within the
ideologically moderate range of 0.1 and 0.1 (conservative
Democrats and liberal Republicans) and who have introduced
HIV/AIDS bills. Of those 11 MCs, only two are Democrats. We
need to look closer at the content of the breakthroughs
and the bills to build on the correlations revealed by the
aggregate- and individual-level analysis.
Congressional attention to HIV/AIDS segregated by topics
A brief summary of the most-cited papers in high-impact
journals reveals a coherent story about how scientific break-
throughs compared with congressional attention. In the
1980s, HIV/AIDS scientific breakthroughs centred on Mon-
tagnier, Barre-Sinnousi and Gallo isolating and culturing HIV,
developing antibodies and research reagents for molecular
and cellular studies and understanding the mechanisms of
infection and transmission [3338]. Identification dominated
major papers in the 1980s (Figure 3A).
Scientific advances in the 1990s shifted towards medicine
and treatment (Figure 3B), as well as pathogenesis and
transmission studies (including comorbidities and the side
effects of antiretrovirals) (Figure 3C and 3D). Key biomedical
findings during this period include sensitive, quantitative
detection of viral RNA [12,39,40] and crystallization of HIV-1
reverse transcriptase [41]. This accelerated the development
of pharmaceutical inhibitors targeting this key enzyme.Today,
these drugs have saved 3 million years of life [42,43] and are
in 100% of HIV medication cocktails.
The earliest scientific discussions on curing the disease
(Figure 3E), in a real sense, began in 1996 after researchers
discovered people who had a CCR5 mutated co-receptor that
inhibited infection and slowed disease progression to AIDS
without the use of antiretrovirals [4447]. Removing long-
term, undetectable-viral-load patients from antiretrovirals
saw rebounded viral loads, plummeting CD4 cells and
the realization that patients were not cured but that viral
reservoirs were established in latent infected cells [48,49].
Figure 1. Aggregate data of five major variables used as metrics for attention to HIV/AIDS in the scientific literature, in the US Congress and
in the popular press. Databases on scientific publications, congressional hearings, bill sponsorship and New York Times articles were searched
to compile data on annual numbers of each during the time period of 19812010, and they were plotted with the number of each for each
year: (A) Bills introduced, (B) hearings held, (C) laws passed, (D) major scientific papers published and (E) New York Times articles published.
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4Scientists then developed fusion and integrase inhibitors to
block the entry and establishment of viral reservoirs in cells
[50]. HIV vaccine development suffered a setback when a
major trial failed in 2003 [51,52]. Lastly, there was a surge in
papers on transmission and on medication and treatment
from 2000 to 2010, once biomedical scientists determined
that successful viral suppression with highly active antire-
troviral therapy (HAART) also lowered the risk of transmission
to non-infected individuals [53,54].
All bills introduced and major papers on HIV/AIDS were
coded according to predetermined subjects. Figure 4 shows
how the legislative agenda for HIV/AIDS changed over time.
During the 1980s, bills were introduced to fund research,
adopt guidelines and programmes for testing, establish social
programmes for PLWHA and help with prevention. By the
1990s, many bills were about maintaining, appropriating and,
in some instances, slashing funding for these established
programmes. The largest correlative peak between the
science of and the congressional response to HIV/AIDS
occurred in 1997 (Figures 3 and 4) with the discovery and
implementation of HAART, the three-drug cocktail, to effec-
tively suppress viral levels [5558], leading to the first-ever
Table 2. Most cited HIV/AIDS paper of each year from 1986 to 2011 with HIV/AIDS as a keyword and search term
Year First author Title Journal
Times
cited
1986 Walker, CM Lymphocytes-CD8 can control HIV-infection in vitro by suppressing virus-replication Science 922
1987 Folks, TM Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell-line Science 761
1988 Pauwels, R Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV
compounds
J Virol Meth 1197
1989 Larder, BA HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 1492
1990 Zack, JA HIV-1 entry into quiescent primary lymphocytes  molecular analysis reveals a labile,
latent viral structure
Cell 1176
1991 Schreck, R Reactive oxygen intermediates as apparently widely used messengers in the activation of
the NFkB and HIV-1
EMBO J 2855
1992 Kohlstaedt, LA Crystal-structure at 3.5 angstrom resolution of HIV-1 reverse-transcriptase complexed
with an inhibitor
Science 1464
1993 Pantaleo, G HIV-infection is active and progressive in lymphoid-tissue during the clinically latent stage
of disease
Nature 1515
1994 Connor, EM Reduction of maternal-infant transmission of human-immunodeficiency-virus type-1 with
zidovudine treatment
NEJM 2112
1995 Ho, DD Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 3073
1996 Heid, CA Real time quantitative PCR Genome Res 3376
1997 Murray, CJL Alternative projections of mortality and disability by cause 19902020: global burden of
disease study
Lancet 2407
1998 Palella, FJ Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection
NEJM 4942
1999 Schmitz, JE Control of viremia in simian immunodeficiency virus infection by CD8() lymphocytes Science 1372
2000 Paterson, DL Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 1421
2001 Garrus, JE Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding Cell 721
2002 Sheehy, AM Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif
protein
Nature 929
2003 Wei, XP Antibody neutralization and escape by HIV-1 Nature 922
2004 Stremlau, M The cytoplasmic body component TRIM5 alpha restricts HIV-1 infection in Old World
monkeys
Nature 692
2005 Mattapallil, JJ Massive infection and loss of memory CD4() Tcells in multiple tissues during acute SIV
infection
Nature 590
2006 Lopez, AD Global and regional burden of disease and risk factors, 2001: systematic analysis of
population health data
Lancet 1161
2007 Gray, RH Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial Lancet 522
2008 Jones, KE Global trends in emerging infectious diseases Nature 481
2009 Rerks-Ngarm, S Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand NEJM 457
2010 Karim, QA Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention
of HIV infection in women
Science 271
2011 Cohen, MS Prevention of HIV-1 infection with early antiretroviral therapy NEJM 147
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5drop in AIDS deaths [59,60].Concurrently,the global epidemic
began to dominate the legislative agenda, accounting for 50%
of all HIV/AIDS bills introduced in this time frame (Figure 4).
This may have been due to major findings from large clinical
trials conducted at foreign research sites, which helped
illuminate the global epidemic to the United States.
Biomedical research breakthroughs foster bipartisan
HIV/AIDS policy
The last piece of the story looks more closely at who sponsors
HIV/AIDS bills. From 1983 to 1994, Democrats dominated the
introduction of bills in response to the HIV/AIDS crisis, but
when Republicans were swept into power in the 1994
midterm elections, there was a stark partisan shift in who
introduced HIV/AIDS bills, and it became a bipartisan issue.
Republicans moved away from punitive ‘‘culture war’’ policies
of the 1990s, and in the early 2000s, powered by the
‘‘compassionate conservatism’’ of President George W.
Bush, joined efforts to fight HIV/AIDS globally, including the
passage of the President’s Emergency Plan for AIDS Relief
(PEPFAR), resulting in a decade of bipartisan HIV/AIDS bill
sponsorship (Figure 5).
Table 5 provides more insight into the politics of congres-
sional attention to HIV/AIDS. Half of the top 10 sponsors of
HIV/AIDS bills represented California. This was the epicentre
of the disease in its early years, so it makes sense that these
MCs would feel a greater need to respond to the crisis. Ted
Kennedy’s senate career was defined by a longstanding
commitment to healthcare issues, so his inclusion at the top
of this list is not surprising. Conservative Republican William
Dannemeyer’s bills are all about required HIV testing and
subsequent prohibitions of PLWHA from various public health
occupations. All of Henry Hyde’s and James Walsh’s bills are
related to their positions as committee and/or subcommittee
chairmen. A closer look at who sponsors HIV/AIDS bills shows
that institutional position, potential constituency pressures,
partisanship and ideology  in other words, politics  are part
of how biomedical breakthroughs are translated into the
congressional response to HIV/AIDS.
Discussion
In the aggregate and at the individual level, science had a
real  although limited  role to play in congressional policy
making concerning HIV/AIDS. For HIV/AIDS, major scientific
papers correlated with bill sponsorship by members of
Congress. Scientific breakthroughs did not impact legislative
hearings or the passage of bills into law. Sponsoring bills
requires lower thresholds of attention, and given this, it
makes sense that biomedical scientific advances matter for
bill sponsorship rather than hearings or laws.
We interpret these results through the lens of the agenda-
setting literature in political science. Accordingly, policy
entrepreneurs define or redefine issues for appeal to broader
audiences, and then those audiences help to break estab-
lished policy monopolies that are keeping new issues off the
agenda [61,27,29,6265]. Bill sponsorship fits into that
entrepreneurial role [66]. Table 5 illustrates that MCs took
on an entrepreneurial role for policy, electoral and institu-
tional reasons [31,67]. Increasing numbers of scientific break-
throughs provide more opportunities for entrepreneurs,
leading to more HIV/AIDS bills being introduced. As seen in
Figures 3 and 4, early breakthroughs were essential to
defining HIV/AIDS as a new national health crisis. Due to
the limits of biomedical science at the time, policy solutions
were education, prevention and research funding. Later
breakthroughs in medical treatments provided for new policy
solutions such as subsidized access to treatment.
Kingdon [62] argues that a well-defined problem and
plausible policy solution are not enough to move items onto
Congress’s formal agenda. It is important to note that our
study concerns only the biomedical science portion of the
HIV/AIDS landscape. Activism around the disease, public
health (as opposed to strictly biomedical) research and other
forms of advocacy are essential for providing a full picture of
how and why Congress paid attention to HIV/AIDS. It is
entirely possible that these other aspects fill in the gaps
that biomedical research leaves regarding hearings and
passing laws.
Table 3. Members of the US Congress are more likely to
introduce HIV/AIDS bills when there have been more major
scientific papers published
Variables Bill sponsorship Hearings Laws
Major papers 0.806 0.056 0.039
0.305 0.091 0.034
0.014 0.546 0.261
Lagged bills 0.017
0.221
0.938
Lagged hearings 0.443
0.293
0.144
Lagged laws 0.192
0.196
0.338
Lagged news 0.038 0.007 0.007
0.011 0.007 0.001
0.002 0.291 6.53E-05
Democrat control 9.981 0.8 1.173
5.449 1.987 0.718
0.079 0.691 0.115
Major events 9.563 6.844 0.366
8.594 3.212 1.173
0.277 0.043 0.758
Log likelihood 308.992 268.715 253.516
N 29 29 29
Effects that major scientific papers about HIV/AIDS had on spon-
soring bills, holding hearings and passing laws were estimated as a
VAR(1) process. The coefficients from that estimation are presented
in Table 3 in boldface, along with the standard errors in roman type
and the p-values in italics. When there are more major scientific
papers published on HIV/AIDS and/or there are more news articles
about HIV/AIDS, then there should be more HIV/AIDS bills introduced
in Congress the following year.
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6Figures 3, 4 and 5 provide a picture of how ideology,
partisanship and science shaped congressional responses. For
its first 15 years, HIV and AIDS were viewed, together,
primarily as the disease of drug addicts and gay White men,
hence the earlier name of GRID. With that, it was relegated
to being a niche liberal issue. The Democrats who controlled
Congress responded with bills for social programmes for
prevention, testing and research, but GRID met the gridlock
of Congress and only as many as eight bills passed per year
out of the 50100 that were introduced (Figure 1). During
this time, scientists worked to isolate and identify this virus
[3338]. In the mid-1990s, Republicans won control of
Congress and scientific breakthroughs shifted towards more
effective medical treatments. Domestically, the newly in-
fected shifted from gay White men more to those who were
Black, Latino, poor, deviant and, in the minds of some,
undeserving of help [6870]. By 2000, Blacks and Latinos had
surpassed Whites in AIDS-related deaths [71]. Globally, there
was an opportunity for Republicans to seize policy initiatives
on HIV/AIDS and build their brand of compassionate
conservatism by using scientific advances in treatments for
HIV/AIDS to provide medicines for poor countries through
PEPFAR.
It is interesting to postulate what role the latest biomedical
breakthroughswill playincongressionalattention and domes-
tic policy going forward, with the success of the CAPRISA
(Centre for the AIDS Programme of Research in South Africa)
trial, in which a vaginal microbicide was shown to reduce
transmission to women through heterosexual contact [72],
and the iPREX (Pre-Exposure Prophylaxis Initiative) trial
that showed the efficacy of pre-exposure prophylaxis (PrEP)
with antiretrovirals in preventing new HIV infections among
men who have sex with men (MSM) [73]. CAPRISA pro-
vides a means for women to protect themselves, but iPREX
Table 4. Independent variables’ effect on the probability of an individual US Congress member introducing HIV/AIDS legislation
Variables Change in probability 95% confidence interval House results Senate results
*Major papers 0.7% [0.5%, 0.9%] 0.6% [0.4, 0.9]* 1.0% [0.5, 1.6]*
*Ideology 2% [2.8%, 1.2%] 2.2% [3.4, 1.3]* 1.9% [4.1, 0.4]*
*Democrat 2.5% [3.7%, 1.6%] 2.8% [4.3, 1.7]* 2.2% [5.2, 0.03]*
*Female 1.1% [0.1%, 2.3%] 2.3% [0.9, 4.3]* 0.7% [2.6, 1.4]
Black 0.1% [1.1%, 1.6%] 0.5% [0.8, 2.0] 7.9% [4.7, 64]
*Majority 2.1% [1.2%, 3.2%] 3.2% [1.9, 4.8]* 1.0% [0.5, 2.9]
*Total bills 2.3% [1.6%, 3.0%] 1.8% [1.2, 2.6]* 2.5% [1.4, 4.1]*
*News 2% [1.4%, 2.9%] 1.4% [0.8, 2.2]* 3.4% [1.6, 5.6]*
Major events 1.1% [0.02%, 2.3%] 1.0% [0.4, 2.5] 1.4% [1.1, 4.4]
Predicted change in the probability of the variable (given in each row) to effect change in an individual Congress member to introduce an HIV/
AIDS bill was derived from multilevel logistic regression. 95% confidence intervals are shown as well. If the confidence interval does not contain
zero, then the predicted change is statistically significant. *Denotes statistical significance. The first two columns are for the full data set that
combines the House and Senate. The last two columns show separate results for House members and Senate members, respectively.
Figure 2. Biomedical breakthroughs and liberal ideology increase sponsorship of HIV/AIDS bills. Predicted probabilities derived from
multilevel logistic regression on individual-level bill sponsorship of HIV/AIDS legislation: (A) The probability of introducing a bill on HIV/AIDS
as the number of scientific breakthroughs increases; and (B) the probability of introducing a bill on HIV/AIDS as ideology moves from liberal
to conservative.
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7demonstrated efficacy for the high-risk (yet still culturally
stigmatized) group of MSM, a group that also does not find
favour with religious and political conservatives.Whether one
will find more favour compared to the other in the eyes of
Congress, to receive federal funds for treatment or public
health distribution, remains to be seen. Perhaps Guston was
rightand the science cannot be separated from the politics, or
at least not in the way that biomedical scientists believe it
should be. Nor can it be separated from advocates and public
health issues to maximize congressional response. Non-
scientific methods mustbe involved as well, and while science
ishelpful,itmustbesupplemented‘‘withtheanalysisofthose
aspects of the human condition that science cannot easily
illuminate’’ [74].
Figure 3. Major scientific breakthrough publications categorized by topic for each year compared to the total number of HIV/AIDS articles
published. The top 500 most-cited papers were categorized according to (A) identification, (B) pathogenesis, (C) transmission, (D) medication
and treatment and (E) cure. Total numbers of papers published per year were calculated and plotted.
Figure 4. Changes in the composition of the HIV/AIDS congressional agenda over 30 years of the epidemic. All HIV/AIDS bills introduced in
Congress from 1981 to 2010 were coded according to subjects and tabulated.
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8Conclusions
We have shown that breakthroughs in biomedical research
did associate with the number and types of HIV/AIDS bills
introduced in Congress, but that relationship did not extend
to passage of laws or to congressional hearings. We began
by asking whether science could shape policy without itself
being shaped by politics. This study makes three contribu-
tions to the literature around that question. Firstly, our
findings are slightly counterintuitive because we show that
science can matter for policy making. The agenda-setting
literature suggests that complex information, like biomedical
research, would not impact bill sponsorship. Secondly, we
provide a more direct quantitative test of the hypothesized
relationship between science and policy. Thirdly, we provide
additional nuance to the science-for-policy debate. We have
argued that biomedical breakthroughs created opportunities
for policy entrepreneurs  that, in effect, science opened a
way for politics. However, the ultimate consequence has
been a depoliticization of HIV/AIDS policy at the congres-
sional level. Scientific breakthroughs helped to transform
HIV/AIDS policy from a niche of liberal Democrats to
bipartisan support to fight the disease globally. In that
regard, these findings bring us closer to Guston’s position.
Science matters when it suits the politics.
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